A Phase II Trial of SU5416 (NSC 696819) [semaxanib] in Patients With Malignant Mesothelioma
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2013
At a glance
- Drugs Semaxanib (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- 26 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Sep 2005 New trial record.